| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
Form 4/A: Hippel James, CFO
Received 9,980 shares by exercise or conversion · Gave up 4,423 shares to cover exercise price or tax ($320K) · Disposed of 34,443 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more |
| 02 Nov 2026 |
Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES
Received 6,547 shares by exercise or conversion · Gave up 2,019 shares to cover exercise price or tax ($146K) · Disposed of 22,545 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more |
| 02 Nov 2026 |
Form 4/A: Kelderman Kim, Director
Received 21,736 shares by exercise or conversion · Gave up 10,955 shares to cover exercise price or tax ($793K) · Disposed of 45,993 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more |
| 02 Nov 2026 |
Form 4/A: Bohnen Shane, SVP - General Counsel
Received 4,420 shares by exercise or conversion · Gave up 1,366 shares to cover exercise price or tax ($98.9K) · Disposed of 11,929 Performance Stock Option (Right to Buy) (Disposition to Issuer) · 1 more |
| 11 Apr 2025 |
Form 4/A: Vessey Rupert, Director
Granted 588 Stock Options (Right to Buy) |
| 03 Feb 2025 |
Form 4/A: McManus Matthew, President - DGS
Granted 15,825 Performance Restricted Stock Units |
| 14 Dec 2023 |
Form 4/A: Bohnen Shane, SVP - General Counsel
Granted 4,802 Restricted Stock Units · Granted 12,924 Stock Option (Right to Buy) |
| 14 Dec 2023 |
Form 4/A: Kelderman Kim, Pres. Diagnostics & Genom
Granted 8,873 Restricted Stock Units · Granted 23,881 Stock Options (Right to Buy) |
| 14 Dec 2023 |
Form 4/A: Hippel James, CFO
Granted 13,865 Restricted Stock Units · Granted 37,314 Stock Options (Right to Buy) |
| 14 Dec 2023 |
Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES
Granted 9,074 Restricted Stock Units · Granted 24,424 Stock Options (Right to Buy) |
| 09 Nov 2023 |
Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES
Granted 19,823 Restricted Stock Units |
| 24 Aug 2023 |
Form 4/A: Bohnen Shane, SVP - General Counsel
Granted 148 Restricted Stock Units · Granted 16,302 Stock Option (Right to Buy) |
| 29 Sep 2022 |
Form 4/A: Geist William, President, Protein Sciences
Granted 2,490 Restricted Stock Units |
| 13 Nov 2020 |
Form 4/A: Hippel James, Chief Financial Officer
Exercised 7,391 Stock Option (Right to Buy) |
| 12 Nov 2020 |
Form 4/A: Hippel James, Chief Financial Officer
Exercised 8,809 Stock Options (Right to Buy) |
| 20 Aug 2015 |
Form 4/A: Eansor Norman David, SVP - Novus Biologicals
Granted 9,375 Stock Option (Right to Buy) · Granted 1,500 Restricted Stock Units |
| 20 Aug 2015 |
Form 4/A: Gavin Robert M., Senior V.P. Protein Platforms
Granted 9,375 Stock Option (Right to Buy) · Granted 1,500 Restricted Stock Units |
| 20 Aug 2015 |
Form 4/A: Veronneau Marcel, SVP - Clinical Controls
Granted 5,625 Stock Option (Right to Buy) · Granted 900 Restricted Stock Units |
| 20 Aug 2015 |
Form 4/A: Furlow Brenda S., SVP - General Counsel
Granted 1,200 Restricted Stock Units · Granted 7,500 Stock Option (Right to Buy) |
| 20 Aug 2015 |
Form 4/A: Kummeth Charles R., Director
Granted 119,275 Stock Option (Right to Buy) · Granted 17,283 Restricted Stock Unit |
Loading...